Last reviewed · How we verify

Iron therapy

GlaxoSmithKline · FDA-approved active Small molecule

Iron therapy replaces depleted iron stores to restore hemoglobin synthesis and correct iron deficiency anemia.

Iron therapy replaces depleted iron stores to restore hemoglobin synthesis and correct iron deficiency anemia. Used for Iron deficiency anemia, Iron supplementation in pregnancy, Iron deficiency due to chronic blood loss.

At a glance

Generic nameIron therapy
SponsorGlaxoSmithKline
Drug classIron supplement
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

Iron is an essential component of hemoglobin, the oxygen-carrying protein in red blood cells. When iron stores are depleted, the body cannot produce sufficient hemoglobin, leading to anemia. Iron supplementation replenishes these stores, enabling normal erythropoiesis and restoration of oxygen-carrying capacity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results